A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
NCT ID: NCT05337124
Last Updated: 2025-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
229 participants
OBSERVATIONAL
2022-04-05
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aurinia Renal Response in Active Lupus With Voclosporin
NCT03021499
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
NCT03597464
Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
NCT05288855
LUPKYNIS Drug-use Results Survey
NCT07053891
Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
NCT05962788
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lupkynis Treatment Group
LUPKYNIS
LUPKYNIS treatment per the approved US Prescribing Information
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LUPKYNIS
LUPKYNIS treatment per the approved US Prescribing Information
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Initiating or have initiated treatment with commercial LUPKYNIS as per US approved Prescribing Information (PI)
* Written informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United BioSource, LLC
INDUSTRY
Aurinia Pharmaceuticals Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aurinia Study Director
Role: STUDY_DIRECTOR
Aurinia Pharmaceuticals Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 00-05
South Gate, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUR-VCS-2021-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.